EUVIMEDEUVIMED entdecken
KorrekturOpen Access · CC BY 4.0

Corrigendum: Targeting the PI3K/AKT/mTOR pathway in lung cancer: mechanisms and therapeutic targeting

Min Qiang, Zhe Chen, Hongyang Liu, Junxue Dong, Kejian Gong, Xinjun Zhang, Peng Huo, Jingjun Zhu, Yifeng Shao, Jinazun Ma, Bowei Zhang, Wei Liu und 1 weitere

Frontiers in Pharmacology · 24.04.2025 · 16

DOI: 10.3389/fphar.2025.1591443 ↗

Kurz gefasst

Korrektur in der Zeitschrift Frontiers in Pharmacology, online erschienen am 24.04.2025. Verfasst von Min Qiang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The First Hospital of Jilin University, Changchun, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The International Agency for Research on Cancer (IARC) predicts that in 2022, lung cancer (LC) will have the highest global rates of incidence at 12.4% and mortality at 18.7% (1). The 2022 report from the China National Cancer Center indicated that the number of LC cases in China will increase to 1,060,600, with 733,300 deaths. LC remains the leading cause of both incidence and mortality (Figure 1) (2). Smoking is the most significant risk factor that markedly increases the incidence of LC. In China, smoking is responsible for approximately 44.7% of reported LC deaths in males and 6.4% in females (3). Based on the morphological characteristics of LC cells, LC is classified into small-cell lung cancer (SCLC, approximately 15%) and non-small-cell lung cancer (NSCLC, approximately 85%) (4). SCLC, with its small cellular morphology, is distinguished by its rapid proliferative kinetics and propensity for swift metastasis to organs, such as the liver and brain, through lymphatic and hematogenous routes. Consequently, the prognosis of SCLC is poor, with a 5-year survival rate less than 7% (5). In contrast, the two predominant histological subtypes of NSCLC are adenocarcinoma (ADC; approximately 50%) and squamous cell carcinoma (SCC; approximately 40%) (6).The high incidence and mortality rates of LC pose significant global health challenges. Therefore, understanding these factors is essential to improve patient outcomes. The incidence of LC largely mirrors smoking rates with a latency period of several decades. Consequently, smoking cessation is considered the most effective strategy to reduce the risk of LC. Other important risk factors include environmental exposure to radon, occupational carcinogens, and preexisting nonmalignant lung diseases. Addressing this challenge requires a comprehensive approach to the various treatment modalities available for managing the complexities of LC.Therapeutic strategies for LC can be classified into five main categories: surgery, chemotherapy, radiotherapy, immunotherapy, and targeted therapy. Multimodal treatment approaches have been used to improve patient survival. However, owing to the challenges of early diagnosis, the overall 5-year survival (OS) rate of LC remains low at only 19%, and therapeutic outcomes are unsatisfactory (1). In recent years, targeted therapy for LC has undergone rapid evolution with significant advancements. Given the high mutation rates in LC, progress in genetic and biomarker detection has made personalized, targeted therapies for individual patients increasingly feasible (7). As the treatment landscape evolves, personalized approaches driven by molecular and genetic insights have become pivotal in improving patient outcomes. Advances in molecular biology hold promise for developing chemopreventive agents that prevent the onset of LC (8). Notably, the phosphatidylinositol-3-kinase (PI3K)/ protein kinase B (AKT)/ mammalian target of rapamycin (mTOR) signaling (PAM) pathway has emerged as a key target for the development of effective therapies.The PAM signaling pathway is a key driver of carcinogenesis and drug resistance in patients with solid tumors. Abnormalities in the PAM signaling pathway are present in approximately 50% of tumors, making it the most frequently activated signaling pathway in human cancers (9). This pathway is regulated by various upstream signaling proteins and plays a crucial role in modulating downstream effectors through interactions with compensatory signaling pathways, particularly the RAF/MEK/ERK pathway. The limited clinical success of targeted therapeutic agents highlights the importance of addressing alterations in the PAM signaling pathway when designing effective personalized treatment strategies (10). The use of inhibitors targeting key molecules within the PAM signaling pathway has garnered significant interest in targeted LC therapy. Indeed, several studies have developed promising inhibitors of this pathway, particularly for NSCLC (11). Several targeted therapies aimed at the PAM signaling pathway, including buparlisib (a PI3K inhibitor), MK2206 (an AKT inhibitor), sirolimus (an mTOR inhibitor), and perifosine (a dual PI3K/AKT inhibitor), are currently undergoing clinical trials for the treatment of LC (12)(13)(14)(15). Furthermore, several preclinical studies on natural compounds have garnered interest, with findings highlighting their potent inhibitory effects on the PAM signaling pathway (16)(17)(18). The high incidence and mortality rates of LC highlight the need for further research and treatment development.In this review, we explored the role of the PAM signaling pathway in tumorigenesis and disease progression and reviewed recent advancements in preclinical studies and clinical trials targeting the PAM signaling pathway, focusing on the potential of natural products as therapeutic agents.PI3K, an enzyme comprising a large family of lipid and serine/threonine kinases (19), is a heterodimeric protein comprising a p110 catalytic subunit and a p85 regulatory subunit (Figure 2) (20). P110 catalytic subunits (p110α, p110β, p110δ, and p110γ) are encoded by PIK3CA, PIK3CB, PIK3CD, and PIK3CG, respectively (21). All p85 regulatory subunits (p85α, p85β, p55α, p55γ, p50α) are encoded by PIKR1 (22). Three types of PI3K (classes I, II, and III) have been identified in mammals. Class I PI3K is further divided into two subtypes: class 1A (p110α, p110β, p110δ) and 1B (p110γ), the most common type of cancer, is normally activated by RTKs, such as Epidermal Growth Factor Receptor (EGFR), insulin-like growth factor receptor (IGF1-R), and human epidermal growth factor receptor 2 (HER2/neu) (23). Conversely, Class IB consists of one of the two regulatory subunits, p101 or p87, and the PIK3CG-encoded isoform, p110γ (22). Class II PI3K comprises three distinct enzymes: PI3K-C2α, PI3K-C2β, and PI3K-C2γ. In contrast, class III PI3K has only one known member, Vacuolar Protein Sorting 34 (Vps34, also known as PI3K-C3), the sole PI3 kinase expressed in all eukaryotes (9). PI3K signaling is one of the most commonly dysregulated pathways in cancer, promoting cell growth, proliferation, and survival (19).Activation of the receptor tyrosine kinase recruits PI3Kα to the plasma membrane, where it phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 3,4,5 triphosphate (PIP3). As a second messenger, PIP3 binds to and recruits various lipid-binding domains of downstream targets, such as the pleckstrin homology (PH), FYVE, phox (PX), C1, and C2 domains, to the cell membrane (24). The PIK3CA mutation, which activates PI3K α, is one of the most common PI3K/AKT activation mechanisms in cancer. Distortion of NF1, MET, ERBB2, and RIT1 can also activate the PI3K signaling pathway (25).The AKT/mTOR signaling pathway is initiated by PI3K activation. AKT, also known as PKB, is a 57-kDa serine/threonine kinase that is a key mediator of growth factor-nduced cell survival. In the mammalian genome, three AKT isoforms have been identified: AKT1, AKT2, and is the crucial in cell binds to PIP3 and the activation of protein kinase and mTOR 2 PI3K activation to the of two in in the activation and in the The of these two is a in the activation of The in and and and regulated this activation plays a key role in AKT activation by at activation of AKT requires at in the and is the kinase responsible for this AKT its of and AKT in its phosphorylates to a for the PI3K/AKT pathway to cell survival of at and to of to activate the pathway, promoting cell cancer cell and by of PI3K and AKT mTOR is a serine/threonine protein kinase that is the catalytic subunit of two protein mTOR and mTOR as a cellular target of rapamycin and is in the of cell and various including cell proliferation, and of mTOR can the growth, proliferation, cell and of NSCLC cells, activation which comprises and is to making it a key target for mTOR particularly inhibitors and are on through one of its activation by phosphorylates at and at and leading to the of activates the and is a of which the PI3K/AKT signaling pathway. Other regulatory factors include the comprising and AKT the promoting the activation of protein by the and the kinase lipid by the factors and by activates AKT at studies have identified as an essential regulatory factor in the PAM signaling pathway as both upstream and downstream effectors in the PI3K pathway or key of this pathway, including AKT, and However, the mechanisms by which these effects to be PAM signaling pathway is a crucial signaling pathway that various cellular including cell growth, proliferation, and and is one of the most commonly dysregulated pathways in cancers and pivotal in of the PAM signaling pathway can and which are with effects the activation of key molecules within this pathway can cancer cell survival by and The of this survival pathway and in cancer PAM signaling pathway is as a in to including insulin-like growth growth factor and epidermal growth factor receptor receptor and are key upstream regulatory factors of the PAM signaling pathway of are with and metastasis cell survival through PI3K/AKT and The of with the of AKT, and with cell alterations targeting the PAM signaling pathway are with cancer the of in the second most common in the human genome, second only to In recent years, the incidence of has been to activation of the PAM signaling pathway or of PI3K can in of this pathway, cancer cell and survival. PI3K and AKT and mTOR the PAM signaling pathway of of cell approaches focusing on and their targeting of are of for the molecular mechanisms the of lung squamous cell carcinoma is in resistance to and survival mTOR is in cancer, leading to protein cell growth, and all essential for progression in of of the (a of the and or mutation of AKT can in the activation of the PAM signaling pathway, cell and survival to its pivotal role in cancer, the PAM signaling pathway is a target for cancer targeting AKT, and mTOR are undergoing clinical trials for various cancer However, drug resistance and within the pathway that the treatment PAM signaling pathway is in and activation of the PAM signaling pathway in This pathway also signaling and making it a key of research in managing and various through of the PAM signaling pathway is a promising strategy the complexities of the PAM signaling pathway is essential for its role in cancer progression and resistance on this the therapeutic focusing on these insights can be to targeted treatment strategies for PAM signaling pathway is one of the most frequently dysregulated in human cancers and plays a role in the and survival of LC In LC cells, this pathway is in the PI3K or of AKT protein are which can cause proliferation, and and of LC Consequently, most of which are targeting these three key have been developed and these have to significant the and potential of these therapies further of inhibitors and their clinical the we inhibitors targeting the AKT, and mTOR of the PAM signaling pathway, their mechanisms of outcomes of clinical and challenges in their use for LC therapy 1) This on these inhibitors the of LC the PAM signaling pathway, PI3K is a drug target for cancer treatment its is with and cancer cell the several have developed PI3K inhibitors to target this key pathway PI3K inhibitors have significant therapeutic human and resistance their clinical a is a of class I PI3K with effects in various solid However, it has been by the and for the treatment of cancer types studies have in or and the of to Therefore, the growth of NSCLC cells, of genetic has a rapid and effective inhibitory on the PAM signaling pathway in human NSCLC SCLC and cell growth by key for cell PI3K such as in with such as and cell The II the of the in patients with NSCLC and PI3K pathway activation that PI3K pathway activation can be it be the driver in Therefore, therapies PI3K inhibitors and agents be effective than is an PI3K with (an significant therapeutic effects cancer in and on in the treatment of patients with NSCLC in with and or or and or The that with various treatment is feasible for NSCLC and findings have indicated is a that has in preclinical both as a and in with cell protein the and targeting the cancer The the indicated that of and in with inhibitors for further in II trials a dual developed by cell and the of by the of PI3K protein and the of AKT protein the and PI3Kα subunits, drug resistance to the of PI3Kα when is clinical is currently the and of with for the treatment of patients with NSCLC is a PI3Kα with high in targeting squamous cell LC with PIK3CA in and in studies the effects of by the signaling pathway activated by PI3K/AKT in NSCLC The of and a on NSCLC PI3K/AKT activation. of PIK3CA to cell and resistance in NSCLC therapy with and is a promising strategy to resistance driven by PI3K/AKT activation for PI3K inhibitors have in preclinical and in can AKT activation of downstream in the PAM signaling pathway. clinical trials are AKT such as and as and in with agents for LC. In has been in solid and However, of these have Notably, is a promising treatment for these patients and is to and in the is a of human AKT1, AKT2, and with preclinical I the of and in NSCLC patients and epidermal growth factor receptor tyrosine kinase inhibitors is an that activates and through AKT leading to activation of also in cancer and growth in studies have that the therapeutic of and by modulating the signaling a II is currently to the of and for the treatment of patients with or NSCLC have or are to a all AKT isoforms and is an effective AKT with an of for all three AKT a of of a large of cell are to with of these cell PIK3CA or is a biomarker of the is an II as a for treatment this to genetic in NSCLC with dual AKT activation and AKT is inhibitors the to clinical activation the of and cell proliferation, and In activation protein including AKT, further cell survival and Therefore, the of both and insights into the targeting of mTOR to tumors. However, the of mTOR inhibitors be limited by compensatory that in AKT activation is an effective and of In sirolimus at as low as mTOR signaling in The report on an mTOR with in that patients the clinical and indicated that sirolimus can be with and to LC or is a rapamycin that by as a of is an drug used to cancer. This cancer cell and to cell survival in patients with cell carcinoma therapies to AKT activation mTOR signaling in human cancer cells, including NSCLC cells, as as in This II, the of in patients with NSCLC undergone than two Research has that when at a of and within its preclinical that and mTOR inhibitors can have or effects in NSCLC by to agents mTOR This that when with and chemotherapy, be an effective treatment for NSCLC is an mTOR kinase with and activates and in and is a potential for therapy with in NSCLC owing its and in and its mechanisms with I the of and in patients with NSCLC of at a of when with the in the this in the a drug only also chemopreventive effects various human including cancer, LC, cancer, and making it a promising frequently tumorigenesis and cancer chemotherapy, and strategies to or have been as potential cancer therapies In LC cells, therapy with and (a a than drug by this the role of from cell to with as a two distinct types of cell and In an in a lung by is an dual I PI3K and mTOR kinase that p110δ, p110β, and significant effects in with as as in NSCLC cell therapy dual NSCLC to the effects of in and in Therefore, dual with patients with NSCLC in the LC to which the of and to effective The significant therapeutic of and highlights its potential importance in cancer treatment of and has a inhibitory on LC cell growth in and in This only AKT and also the inhibitory on and this when the of both it effective is a and tyrosine kinase that cell growth by in In to its inhibitory effects on cell proliferation, and making it a for cancer particularly for LC and cancer the therapy of and the class I PI3K in patients with focusing on with alterations in PI3K pathway molecules and known of II treatment with or with to patients with NSCLC The in patients with the of and in a rate and survival than the of in this of NSCLC patients is an The of and both and have that and inhibitors can the growth of by mutation, and This treatment strategy a approach to these several targeting the PAM signaling pathway have been research on natural products promising the of natural products in targeting the PAM signaling pathway and their and from natural products have garnered As a of used in disease several including low and to cancer therapy. studies have the of various with in and when with treatment modalities 2) and effects by targeting and these the to with a of The interactions and and and the and of cells, cell and and of and in drug a crucial role through signaling pathways to its cell and cancer cell growth by the and signaling pathways is a from of the with including is a from and is of and with an molecular of approximately a of including effects and the of PI3K and its downstream target AKT in a and mTOR in a In two downstream of and which are of mTOR In LC cells, by the PAM signaling pathway, cancer cell and a from significant NSCLC both in and in is an in the family commonly is for its various and and including and essential and are to advancements in targeted therapies that can and cancer cells, making one of the most for their and the years, have garnered significant for their potent and making for various through the of In studies have that by This that the of the of and The of the of PI3K subtypes such as and findings that cell by the signaling pathway is a from the and of and including for the that treatment with to the of to and promoting the of This a approach for targeted therapy of cancer PAM signaling pathway plays a pivotal role in the and survival of The of the the PAM signaling pathway is the or of cell through signaling a for growth, and comprises various cells, cells, and signaling The PAM signaling pathway plays a pivotal role in the interactions and their particularly and cell and (Figure the interactions key in the and PAM signaling are the most cellular in the and an are a significant of factors that growth, and and to by and these and plays a crucial role in Therefore, is a potential therapeutic target for tumors. The PAM signaling pathway plays a key role in the and of activation of the PAM signaling pathway the of the their such as the of and promoting the of that the PAM signaling pathway, such as PI3K the of from the type to the the are and that and are with This the of the to studies have that the and of are with an to therapy in various solid of the PAM signaling pathway in can their The of the PAM signaling pathway can the and of particularly with low of studies have that can the PAM signaling pathway, the of to tumors. Consequently, has emerged as a promising target for the of therapy inhibitors can the of improving the of tumors. by the PAM signaling pathway, which the This is a key of with to the of by targeting the PAM signaling pathway. to the is in with its regulatory subunits and is in the where is the catalytic subunit for PI3K activate p110γ through a receptor tyrosine kinases and activate p110γ a p110γ the activation of the the of into tumors. or genetic of p110γ growth, and metastasis in both and in most cells, both at the and its role in AKT is essential for the of both and and AKT2, of the development of and cell findings insights into cell and cancer In AKT plays a role in by cell in a by the of In contrast, in and in cell activation through and the downstream of and by type in an In contrast, the of and by type 2 of is considered a an important role in cell and the signaling pathway in a potential strategy for studies have that is in an by in the pathway is a key to the of is the catalytic of the and and its activation is essential for the activation and of cellular the by which mTOR the in

Schlagwörter

Stichwörter der Autor:innen

Akt inhibitorsPI3K inhibitorsPI3K/Akt/mTOR pathwaycombined therapylung cancermTOR inhibitorsnatural products

Autor:innen und Institutionen

  • Department of Thoracic Surgery, The First Hospital of Jilin University, Changchun, China.
  • College of Clinical Medicine, Jilin University, Changchun, China.
  • Department of Molecular Biology, Max Planck Institute for Infection Biology, Berlin, Germany.
  • Laboratory of Infection Oncology, Institute of Clinical Molecular Biology, Christian-Albrechts-Universität zu Kiel and University Hospital Schleswig-Holstein, Kiel, Germany.
  • Department of Thoracic and Cardiovascular Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Department of General Surgery, Capital Institute of Pediatrics' Children's Hospital, Beijing, China.

Zitieren

APA

Qiang, M., Chen, Z., Liu, H., Dong, J., Gong, K., Zhang, X., Huo, P., Zhu, J., Shao, Y., Ma, J., Zhang, B., Liu, W., & Tang, M. (2025). Corrigendum: Targeting the PI3K/AKT/mTOR pathway in lung cancer: mechanisms and therapeutic targeting. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1591443

Vancouver

Qiang M, Chen Z, Liu H, Dong J, Gong K, Zhang X, et al. Corrigendum: Targeting the PI3K/AKT/mTOR pathway in lung cancer: mechanisms and therapeutic targeting. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1591443

BibTeX
@article{Qiang2025,
  author = {Qiang, Min and Chen, Zhe and Liu, Hongyang and Dong, Junxue and Gong, Kejian and Zhang, Xinjun and Huo, Peng and Zhu, Jingjun and Shao, Yifeng and Ma, Jinazun and Zhang, Bowei and Liu, Wei and Tang, Mingbo},
  title = {Corrigendum: Targeting the PI3K/AKT/mTOR pathway in lung cancer: mechanisms and therapeutic targeting},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fphar.2025.1591443}
}
Kostenlos starten →